Show simple item record

dc.contributor.authorBrahe, Cecilie Heegaard
dc.contributor.authorØrnbjerg, Lykke Midtbøll
dc.contributor.authorJacobsson, Lennart
dc.contributor.authorNissen, Michael J
dc.contributor.authorKristianslund, Eirik Klami
dc.contributor.authorMann, Herman
dc.contributor.authorSantos, Maria José
dc.contributor.authorReino, Juan Gómez
dc.contributor.authorNordström, Dan
dc.contributor.authorRotar, Ziga
dc.contributor.authorGudbjornsson, Bjorn
dc.contributor.authorOnen, Fatos
dc.contributor.authorCodreanu, Catalin
dc.contributor.authorLindström, Ulf
dc.contributor.authorMöller, Burkhard
dc.contributor.authorKvien, Tore K
dc.contributor.authorPavelka, Karel
dc.contributor.authorBarcelos, Anabela
dc.contributor.authorSánchez-Piedra, Carlos
dc.contributor.authorEklund, Kari K
dc.contributor.authorTomšič, Matija
dc.contributor.authorLove, Thorvardur Jon
dc.contributor.authorCan, Gercek
dc.contributor.authorIonescu, Ruxandra
dc.contributor.authorLoft, Anne Gitte
dc.contributor.authorvan der Horst-Bruinsma, I E
dc.contributor.authorMacfarlane, Gary J
dc.contributor.authorIannone, Florenzo
dc.contributor.authorHyldstrup, Lise Hejl
dc.contributor.authorKrogh, Niels Steen
dc.contributor.authorØstergaard, Mikkel
dc.contributor.authorHetland, Merete Lund
dc.date.accessioned2020-08-31T11:24:54Z
dc.date.available2020-08-31T11:24:54Z
dc.date.issued2020-07
dc.date.submitted2020-08
dc.identifier.citationBrahe CH, Ørnbjerg LM, Jacobsson L, et al. Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA. Rheumatology (Oxford). 2020;59(7):1640-1650. doi:10.1093/rheumatology/kez427en_US
dc.identifier.pmid31665497
dc.identifier.doi10.1093/rheumatology/kez427
dc.identifier.urihttp://hdl.handle.net/2336/621496
dc.descriptionTo access publisher's full text version of this article click on the hyperlink belowen_US
dc.description.abstractObjective: To investigate TNF inhibitor (TNFi) retention and response rates in European biologic-naïve patients with PsA. Methods: Prospectively collected data on PsA patients in routine care from 12 European registries were pooled. Heterogeneity in baseline characteristics between registries were explored (analysis of variance and pairwise comparison). Retention rates (Kaplan-Meier), clinical remission [28-joint count DAS (DAS28) <2.6; 28 joint Disease Activity index for Psoriatic Arthritis ⩽4] and ACR criteria for 20% improvement (ACR20)/ACR50/ACR70 were calculated, including LUNDEX adjustment. Results: Overall, 14 261 patients with PsA initiated a first TNFi. Considerable heterogeneity of baseline characteristics between registries was observed. The median 12-month retention rate (95% CI) was 77% (76, 78%), ranging from 68 to 90% across registries. Overall, DAS28/28 joint Disease Activity index for Psoriatic Arthritis remission rates at 6 months were 56%/27% (LUNDEX: 45%/22%). Six-month ACR20/50/70 responses were 53%/38%/22%, respectively. In patients initiating a first TNFi after 2009 with registered fulfilment of ClASsification for Psoriatic ARthritis (CASPAR) criteria (n = 1980) or registered one or more swollen joint at baseline (n = 5803), the retention rates and response rates were similar to those found overall. Conclusion: Approximately half of >14 000 patients with PsA who initiated first TNFi treatment in routine care were in DAS28 remission after 6 months, and three-quarters were still on the drug after 1 year. Considerable heterogeneity in baseline characteristics and outcomes across registries was observed. The feasibility of creating a large European database of PsA patients treated in routine care was demonstrated, offering unique opportunities for research with real-world data. Keywords: DAPSA28; DAS28; TNFi; drug survival; effectiveness; epidemiology; psoriatic arthritis; register; response; spondyloarthritis.en_US
dc.description.sponsorshipNovartisen_US
dc.language.isoenen_US
dc.publisherOxford University Pressen_US
dc.relation.urlhttps://academic.oup.com/rheumatology/article/59/7/1640/5609873en_US
dc.rights© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
dc.subjectDAPSA28en_US
dc.subjectDAS28en_US
dc.subjectTNFien_US
dc.subjectdrug survivalen_US
dc.subjecteffectivenessen_US
dc.subjectepidemiologyen_US
dc.subjectpsoriatic arthritisen_US
dc.subjectregisteren_US
dc.subjectresponseen_US
dc.subjectspondyloarthritisen_US
dc.subjectSóríasisen_US
dc.subjectLyfhrifafræðien_US
dc.subject.meshArthritis, Psoriaticen_US
dc.subject.meshDrug Therapyen_US
dc.titleRetention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA.en_US
dc.typeArticleen_US
dc.identifier.eissn1462-0332
dc.contributor.department1EuroSpA Coordinating Center, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup. 2DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark. 3Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden. 4Department of Rheumatology, Geneva University Hospital, Geneva, Switzerland. 5Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway. 6Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic. 7Reuma.pt registry and Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal. 8Research Unit, Spanish Society of Rheumatology, Madrid, Spain. 9ROB-FIN Registry, Helsinki University and Helsinki University Hospital, Helsinki, Finland. 10biorx.si and the Department of Rheumatology, University Medical Centre Ljubljana, Slovenia, Ljubljana. 11Centre for Rheumatology Research, University Hospital and Faculty of Medicine, University of Iceland, Reykjavik, Iceland. 12TURKBIO Registry and Division of Rheumatology, School of Medicine Dokuz Eylul University, Izmir, Turkey. 13Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania. 14Leitender Arzt der Universitätsklinik für Rheumatologie, Immunologie und Allergologie Inselspital, Bern, Switzerland. 15Rheuma.pt registry, Rheumatology Department-Centro Hospitalar do Baixo Vouga and Ibimed-Institute for Biomedicine, University of Aveiro, Aveiro, Portugal. 16Inflammation Center, Department of Rheumatology, Helsinki University Hospital, Helsinki, Finland. 17University of Iceland, Faculty of Medicine, and Landspitali University Hospital, Reykjavik, Iceland. 18Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark. 19Amsterdam Rheumatology & immunology Center (ARC), Academic Medical Center, Amsterdam. 20Department of Rheumatology, Amsterdam UMC, VU University Medical Centre Amsterdam, Amsterdam, The Netherlands. 21Epidemiology Group, School of Medicine, Medical Science and Nutrition, University of Aberdeen, Aberdeen, UK. 22GISEA registry, Rheumatology Unit - DETO, University of Bari, Bari, Italy. 23Zitelabs Aps, Copenhagen. 24Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.en_US
dc.identifier.journalRheumatology (Oxford, England)en_US
dc.rights.accessLandspitali Access - LSH-aðganguren_US
dc.departmentcodeRHE12
dc.source.journaltitleRheumatology (Oxford, England)
dc.source.volume59
dc.source.issue7
dc.source.beginpage1640
dc.source.endpage1650
dc.source.countryEngland


This item appears in the following Collection(s)

Show simple item record